PSMA Imaging Is Redrawing the Boundary Between Watchful Waiting and Treatment
Rising PSA after prostate surgery or radiation has long created a difficult gray zone in prostate cancer care. The cancer is back in biochemical form, yet conventional scans still show no visible disease, leaving clinicians to balance the pace of the PSA rise against the toxicity of treatment. For many men, that uncertainty has supported a deliberate delay in hormonal therapy, especially when the PSA climbs slowly and the person remains asymptomatic.
A newer imaging tool has changed the conversation. PSMA scanning can reveal very small deposits of prostate cancer by binding to prostate-specific membrane antigen on tumor cells, exposing lesions that bone scans and MRI may miss. When those tiny metastases appear in a man who would once have been labeled as having biochemical recurrence, the disease state has been described as (PSMA) + BCR.
The scan can reveal disease, but the biology does not automatically demand immediate escalation.
Small PSMA-Detected Lesions Do Not Always Behave Like Aggressive Metastatic Disease
The central clinical problem is straightforward: should a positive PSMA scan trigger treatment as if the patient has established metastatic disease, or can some men still be monitored safely? In routine practice, many clinicians react to visible metastases with earlier and more intensive therapy, often combining testosterone suppression with other hormonal agents that bring meaningful side effects. Yet the presence of tiny PSMA-detected lesions does not guarantee rapid progression, and that distinction is forcing a reevaluation of reflexive treatment.
David Einstein, who leads the Genitourinary Medical Oncology Program at Beth Israel Deaconess Medical Center and teaches at Harvard Medical School, has argued that some men with PSMA-detected recurrence may live for years without a major cancer-related event. He has pointed to the broader experience with biochemical recurrence, where survival can extend a decade or more and some men never develop overt metastases. On that basis, a subset of men with PSMA-only recurrence may face no imminent threat from the cancer, even if the scan looks alarming.
The underlying reason is biological as much as clinical. PSA is a sensitive marker of residual disease, but it does not measure growth rate by itself, and not every tumor clone detected early is destined to become clinically dominant. Some lesions may remain indolent for long periods, while others accelerate quickly. A scan that finds disease earlier may improve anatomical clarity, but it does not automatically prove that earlier treatment will improve survival.
Why Earlier Hormonal Therapy Can Become Overtreatment
Hormonal therapy remains the default systemic treatment when prostate cancer recurs. These drugs lower testosterone or block its effect, and that can slow tumor growth and hold PSA down. They can also bring a substantial burden of adverse effects, especially when used for prolonged periods in men who may not yet need them.
The tradeoff is easy to miss in a clinic visit focused on a scan image. If a man has a few small PSMA-positive lesions but is otherwise well, immediate treatment may add years of fatigue, sexual dysfunction, hot flashes, metabolic effects, and other toxicities without a proven survival gain. For some patients, that is a poor exchange. Delaying therapy can preserve quality of life while the disease is watched carefully, especially when the PSA doubling time is long and imaging shows only a limited burden of disease.
Evidence still falls short of showing that treating biochemical recurrence itself improves survival, although treatment can delay progression and keep PSA from rising further. In that sense, earlier intervention may change the timing of recurrence rather than the end result. The difference matters in men whose natural history is slow enough that they may die of unrelated causes before prostate cancer becomes dangerous.
PSA Doubling Time, Tumor Burden, and Age Still Guide the Decision
Einstein’s framework for managing PSMA-detected recurrence relies on clinical context rather than scan positivity alone. Age and overall health come first. An older man with heart disease or frailty may be less likely to benefit from aggressive treatment than from careful observation, particularly if the cancer is moving slowly.
The original cancer biology also matters. Men whose initial tumors were high grade or carried aggressive features deserve closer attention, and a rapid return after primary treatment raises concern for more active disease. PSA kinetics remain one of the strongest practical signals in the room; the fastest PSA doubling times carry the highest short-term risk of metastasis and should at least prompt discussion of early treatment.
Tumor count on the PSMA scan adds another layer. When fewer than five lesions are seen, some clinicians may treat the visible sites directly with radiation. Monitoring remains reasonable in selected men without other high-risk features. A temporary course of hormonal therapy is sometimes added, but whether that improves the effect of radiation in this setting remains uncertain.
The New Imaging Era Demands Better Natural-History Data
Researchers are now studying the natural history of prostate cancers that recur and are detected only with PSMA imaging. That work is essential because the scan has arrived faster than the evidence base needed to interpret it. Clinicians can see more disease, but they still need to know which lesions will matter, how soon they will spread, and which men can safely defer therapy.
Future trials are being developed to test treatments that may deliver longer-lasting benefit than standard hormonal approaches. Until those data arrive, the most defensible strategy is individualized care: age, comorbidity, initial tumor grade, PSA doubling time, scan burden, and patient preferences all belong in the decision.
Marc B. Garnick, who edits the Harvard Medical School Guide to Prostate Diseases, described PSMA scanning as technology that has raised treatment questions now being actively studied. He also pointed to the value of postponing treatments that used to be given immediately, a strategy many patients accept when the disease is visible but not clearly dangerous.
That approach leaves one practical reality in place: a positive PSMA scan is not, by itself, a mandate for immediate systemic therapy. The challenge is to avoid treating a biological signal as though it were already a clinical emergency.